229 related articles for article (PubMed ID: 25651718)
1. Urinary podocyte can be an indicator for the pathogenetic condition of patients with IgA nephropathy.
Shen P; Shen J; Li W; He L
Clin Lab; 2014; 60(10):1709-15. PubMed ID: 25651718
[TBL] [Abstract][Full Text] [Related]
2. Relationships between levels of urinary podocalyxin, number of urinary podocytes, and histologic injury in adult patients with IgA nephropathy.
Asao R; Asanuma K; Kodama F; Akiba-Takagi M; Nagai-Hosoe Y; Seki T; Takeda Y; Ohsawa I; Mano S; Matsuoka K; Kurosawa H; Ogasawara S; Hirayama Y; Sekine S; Horikoshi S; Hara M; Tomino Y
Clin J Am Soc Nephrol; 2012 Sep; 7(9):1385-93. PubMed ID: 22700887
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of renal clinicopathological changes in IgA nephropathy by urinary podocytes excretion and podocalyxin expression.
Jiang WL; Peng YM; Liu YH; Liu H; Chen GC; Xu XQ; Zhu XJ; Liu FY
Ren Fail; 2012; 34(7):821-6. PubMed ID: 22679920
[TBL] [Abstract][Full Text] [Related]
4. Urine podocyte mRNAs mark disease activity in IgA nephropathy.
Fukuda A; Sato Y; Iwakiri T; Komatsu H; Kikuchi M; Kitamura K; Wiggins RC; Fujimoto S
Nephrol Dial Transplant; 2015 Jul; 30(7):1140-50. PubMed ID: 25956757
[TBL] [Abstract][Full Text] [Related]
5. Urinary and glomerular podocytes in patients with chronic kidney diseases.
Hanamura K; Tojo A; Fujita T
Clin Exp Nephrol; 2014 Feb; 18(1):95-103. PubMed ID: 23670304
[TBL] [Abstract][Full Text] [Related]
6. Effects of angiotensin-converting enzyme inhibitor, angiotensin II receptor antagonist and calcium antagonist on urinary podocytes in patients with IgA nephropathy.
Nakamura T; Ushiyama C; Suzuki S; Hara M; Shimada N; Sekizuka K; Ebihara I; Koide H
Am J Nephrol; 2000; 20(5):373-9. PubMed ID: 11092994
[TBL] [Abstract][Full Text] [Related]
7. Translocation of dendrin to the podocyte nucleus in acute glomerular injury in patients with IgA nephropathy.
Kodama F; Asanuma K; Takagi M; Hidaka T; Asanuma E; Fukuda H; Seki T; Takeda Y; Hosoe-Nagai Y; Asao R; Horikoshi S; Tomino Y
Nephrol Dial Transplant; 2013 Jul; 28(7):1762-72. PubMed ID: 23143340
[TBL] [Abstract][Full Text] [Related]
8. Podocytopenia and disease severity in IgA nephropathy.
Lemley KV; Lafayette RA; Safai M; Derby G; Blouch K; Squarer A; Myers BD
Kidney Int; 2002 Apr; 61(4):1475-85. PubMed ID: 11918755
[TBL] [Abstract][Full Text] [Related]
9. Urinary excretion of β2-microglobulin as a prognostic marker in immunoglobulin A nephropathy.
Shin JR; Kim SM; Yoo JS; Park JY; Kim SK; Cho JH; Jeong KH; Lee TW; Ihm CG
Korean J Intern Med; 2014 May; 29(3):334-40. PubMed ID: 24851068
[TBL] [Abstract][Full Text] [Related]
10. Urine markers of podocyte dysfunction: a review of podocalyxin and nephrin in selected glomerular diseases.
Akankwasa G; Jianhua L; Guixue C; Changjuan A; Xiaosong Q
Biomark Med; 2018 Aug; 12(8):927-935. PubMed ID: 29976076
[TBL] [Abstract][Full Text] [Related]
11. Apical cell membranes are shed into urine from injured podocytes: a novel phenomenon of podocyte injury.
Hara M; Yanagihara T; Kihara I; Higashi K; Fujimoto K; Kajita T
J Am Soc Nephrol; 2005 Feb; 16(2):408-16. PubMed ID: 15625073
[TBL] [Abstract][Full Text] [Related]
12. Podocyte injury induced by mesangial-derived cytokines in IgA nephropathy.
Lai KN; Leung JC; Chan LY; Saleem MA; Mathieson PW; Tam KY; Xiao J; Lai FM; Tang SC
Nephrol Dial Transplant; 2009 Jan; 24(1):62-72. PubMed ID: 18685143
[TBL] [Abstract][Full Text] [Related]
13. [Significance of detecting urinary podocytes in patients with active glomerulonephritis].
Li JZ; Huang HC; Liu Y; E J
Beijing Da Xue Xue Bao Yi Xue Ban; 2005 Oct; 37(5):463-6. PubMed ID: 16224513
[TBL] [Abstract][Full Text] [Related]
14. Urinary podocalyxin, the novel biomarker for detecting early renal change in obesity.
Suwanpen C; Nouanthong P; Jaruvongvanich V; Pongpirul K; Pongpirul WA; Leelahavanichkul A; Kanjanabuch T
J Nephrol; 2016 Feb; 29(1):37-44. PubMed ID: 25905599
[TBL] [Abstract][Full Text] [Related]
15. Urinary excretion of podocytes reflects disease activity in children with glomerulonephritis.
Hara M; Yanagihara T; Takada T; Itoh M; Matsuno M; Yamamoto T; Kihara I
Am J Nephrol; 1998; 18(1):35-41. PubMed ID: 9481437
[TBL] [Abstract][Full Text] [Related]
16. [A study of urinary podocalyxin in children with IgA nephropathy].
Okubo S
Nihon Jinzo Gakkai Shi; 1995 Jul; 37(7):357-65. PubMed ID: 7637206
[TBL] [Abstract][Full Text] [Related]
17. Synergistic effect of mesangial cell-induced CXCL1 and TGF-β1 in promoting podocyte loss in IgA nephropathy.
Zhu L; Zhang Q; Shi S; Liu L; Lv J; Zhang H
PLoS One; 2013; 8(8):e73425. PubMed ID: 24023680
[TBL] [Abstract][Full Text] [Related]
18. Mitofusin2 expression is associated with podocyte injury in IgA nephropathy.
Tang X; Yuan Y; Liang X; Jiang X
Eur J Med Res; 2023 Mar; 28(1):142. PubMed ID: 36998021
[TBL] [Abstract][Full Text] [Related]
19. Cumulative excretion of urinary podocytes reflects disease progression in IgA nephropathy and Schönlein-Henoch purpura nephritis.
Hara M; Yanagihara T; Kihara I
Clin J Am Soc Nephrol; 2007 Mar; 2(2):231-8. PubMed ID: 17699418
[TBL] [Abstract][Full Text] [Related]
20. [Expression and clinical implication of platelet-derived growth factor-D and platelet-derived growth factor-beta in childhood IgA nephropathy].
Rong ZH; Wang C; Hao J; Duan HJ
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2008 May; 20(5):275-8. PubMed ID: 18471357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
